Highlights from EAU 2024: key advances in the diagnosis and treatment of prostate cancer
-
摘要: 目的：2024年4月5—8日，欧洲泌尿外科协会(EAU)年会在法国巴黎召开，展示了世界各地泌尿领域的开拓性研究及最新进展。本文就会议前沿的前列腺癌筛查、诊断方式、手术创新、药物治疗等方面作简要介绍。Abstract: The European Association of Urology (EAU) Annual Congress was held in Paris, France from April 5th to 8th, 2024, bringing together urologists from around the world to discuss the latest researches and advances in the field. The meeting covered a wide range of topics, including prostate cancer screening, diagnosis, surgical innovation and medicine treatment.
-
Key words:
- prostate cancer /
- screening /
- diagnosis /
- surgical innovation /
- drug treatment
-
-
[1] Matsukawa A, Yanagisawa T, Bekku K, et al. Comparing the performance of digital rectal examination and PSA as a screening test for prostate cancer: a systematic review and meta-analysis[J]. Eur Urol, 2024, 85: S413-S414. doi: 10.1016/S0302-2838(24)00375-0
[2] Cirulli GO, Finati M, Chiarelli G, et al. Testing free PSA percentage as a tool in predicting future risk of developing prostate cancer: a system wide analysis of a contemporary North American cohort[J]. Eur Urol, 2024, 85: S435. doi: 10.1016/S0302-2838(24)00391-9
[3] Cirulli GO, Davis M, Finati M, et al. Superiority of midlife baseline prostate-specific antigen value over PSA doubling time and velocity in the prediction of lethal prostate cancer development, and mortality: a system wide analysis of a racially diverse North American cohort[J]. Eur Urol, 2024, 85: S1615. doi: 10.1016/S0302-2838(24)01240-5
[4] Möller F, Masson M, Wallström J, et al. The role of PSA density in the follow up of men with negative MRIin Göteborg 2 trail[C]. Paris: the 39th Annual EAU Congress, 2024.
[5] Cirulli GO, Finati M, Chiarelli G, et al. Comparing PSA screening patterns and their role as predictor of prostate cancer incidence and mortality: a system wide analysis of a contemporary North American cohort[J]. Eur Urol, 2024, 85: S434. doi: 10.1016/S0302-2838(24)00390-7
[6] Fanelli A, Finati M, Falagario UG, et al. Impact of magnetic resonance imaging scan and image acquisition protocol in detecting clinically significant prostate cancer at biopsy: Results from the PROMOD working group[J]. Eur Urol, 2024, 85: S448-S449.
[7] Malshy K, Ochsner A, Ortiz R, et al. Comparison of the incidence of clinically significant prostate cancer in patients with isolated peripheral vs transitional zone PIRADS 3 lesions[J]. Eur Urol, 2024, 85: S445. doi: 10.1016/S0302-2838(24)00399-3
[8] Flammia RS, Proietti F, Chiacchio G, et al. Negative fusion biopsy in PIRADS 3-5 cases: What comes next in real world clinical practice?[J]. Eur Urol, 2024, 85: S474-S475. doi: 10.1016/S0302-2838(24)00416-0
[9] Krausewitz P, Gaertner FC, Essler M, et al. DEPROMP-Study: PSMA-PET/CT prior to prostate biopsy: Enhancing prostate cancer detection and personalized management[J]. Eur Urol, 2024, 85: S471. doi: 10.1016/S0302-2838(24)00414-7
[10] Niu S, Wang BJ, Liu YC, et al. Radical prostatectomy without prior biopsy in selected patients evaluated by 18F-labeled PSMA-ligand positron emission tomography/computed tomography and multiparameter magnetic resonance imaging: a single-centre, prospective, single-arm trial[J]. Eur Urol, 2024, 85: S480-S481. doi: 10.1016/S0302-2838(24)00420-2
[11] Preisser F, Nohe F, Maurer T, et al. Correlation of intraprostatic SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy[J]. Eur Urol, 2024, 85: S479. doi: 10.1016/S0302-2838(24)00419-6
[12] Light A, Lazic S, Houghton K, et al. Determining an optimal SUVmax cut-off for detection of intra-prostatic radiorecurrent prostate cancer using 68Ga-PSMA-11 PET/CT[J]. Eur Urol, 2024, 85: S477-S478. doi: 10.1016/S0302-2838(24)00418-4
[13] Checcucci E, De Cillis ST, Amparore D, et al. Artificial intelligence 3D augmented reality guided RARP vs Cognitive MRI intervention: Ad interim analysis of RIDERS Trial[J]. Eur Urol, 2024, 85: S556. doi: 10.1016/S0302-2838(24)00475-5
[14] Piramide F, Amparore D, Checcucci E, et al. Surgical and new generation imaging tips and tricks to maximize robotic radical prostatectomy outcomes[J]. Eur Urol, 2024, 85: S595. doi: 10.1016/S0302-2838(24)00508-6
[15] Ploussard G, Villers A, Chevallier T, et al. High intensity focused ultrasounds vs radical prostatectomy: Carcinologic results of the HIFI study[J]. Eur Urol, 2024, 85: S1632. doi: 10.1016/S0302-2838(24)01252-1
[16] Karim A, Emily A, Daniel D, et al. Pelvic lymph node dissection in prostate cancer: Update of the limited vs. Extended randomized clinical trail[C]. Paris: The 39th Annual EAU Congress, 2024.
[17] Devos GT, Tosco L, Baldewijns M, et al. Three-year oncological outcomes of the randomized phase Ⅱ trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer[J]. Eur Urol, 2024, 85: S1514. doi: 10.1016/S0302-2838(24)01175-8
[18] De Giorgi U, Freedland SJ, Rannikko A, et al. Enzalutamide(enza) with or without leuprolide in patients(pts)with European Association of Urology(EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer(BCR)following Radical Prostatectomy(RP)or Radiation Therapy(RT): EMBARK post hoc analysis[J]. Eur Urol, 2024, 85: S213-S214. doi: 10.1016/S0302-2838(24)00232-X
[19] Lin E, Garmo H, Robinson D, et al. Duration of use of androgen deprivation therapy after radical therapy for prostate cancer: Nationwide, population-based study[J]. Eur Urol, 2024, 85: S1412. doi: 10.1016/S0302-2838(24)01100-X
[20] Sayyid RK, Klaassen Z, Berlin A, et al. PARP Inhibitor Plus Androgen Receptor Pathway inhibitor combinations for 1st line mCRPC: a systematic review and meta-analysis[J]. Eur Urol, 2024, 85: S1568. doi: 10.1016/S0302-2838(24)01208-9
-
计量
- 文章访问数: 426
- 施引文献: 0
下载: